These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
127 related articles for article (PubMed ID: 34007063)
1. Post-market safety and efficacy profile of subcutaneous testosterone enanthate-autoinjector: a cohort analysis. Choi EJ; Xu P; El-Khatib FM; Kavoussi PK; Yafi FA Int J Impot Res; 2022 Aug; 34(5):467-470. PubMed ID: 34007063 [TBL] [Abstract][Full Text] [Related]
2. Comparison of Outcomes for Hypogonadal Men Treated with Intramuscular Testosterone Cypionate versus Subcutaneous Testosterone Enanthate. Choi EJ; Xu P; Barham D; El-Khatib FM; Yafi FA; Kavoussi PK J Urol; 2022 Mar; 207(3):677-683. PubMed ID: 34694927 [TBL] [Abstract][Full Text] [Related]
3. Safety of a New Subcutaneous Testosterone Enanthate Auto-Injector: Results of a 26-Week Study. Gittelman M; Jaffe JS; Kaminetsky JC J Sex Med; 2019 Nov; 16(11):1741-1748. PubMed ID: 31551193 [TBL] [Abstract][Full Text] [Related]
4. Prostate-specific antigen changes and prostate cancer in hypogonadal men treated with testosterone replacement therapy. Coward RM; Simhan J; Carson CC BJU Int; 2009 May; 103(9):1179-83. PubMed ID: 19154450 [TBL] [Abstract][Full Text] [Related]
5. Influence of demographic factors and biochemical characteristics on the prostate-specific antigen (PSA) response to testosterone replacement therapy. Rhoden EL; Morgentaler A Int J Impot Res; 2006; 18(2):201-5. PubMed ID: 16177827 [TBL] [Abstract][Full Text] [Related]
6. Retrospective investigation of testosterone undecanoate depot for the long-term treatment of male hypogonadism in clinical practice. Conaglen HM; Paul RG; Yarndley T; Kamp J; Elston MS; Conaglen JV J Sex Med; 2014 Feb; 11(2):574-82. PubMed ID: 24279472 [TBL] [Abstract][Full Text] [Related]
7. Summative Usability Evaluation of the SCTE-AI Device: A Novel Prefilled Autoinjector for Subcutaneous Testosterone Administration. Arora S; Moclair B; Murphy K; Jaffe JS; Kaminetsky JC J Sex Med; 2018 Dec; 15(12):1707-1715. PubMed ID: 30393104 [TBL] [Abstract][Full Text] [Related]
8. Prostate Safety Events During Testosterone Replacement Therapy in Men With Hypogonadism: A Randomized Clinical Trial. Bhasin S; Travison TG; Pencina KM; O'Leary M; Cunningham GR; Lincoff AM; Nissen SE; Lucia MS; Preston MA; Khera M; Khan N; Snabes MC; Li X; Tangen CM; Buhr KA; Thompson IM JAMA Netw Open; 2023 Dec; 6(12):e2348692. PubMed ID: 38150256 [TBL] [Abstract][Full Text] [Related]
9. Prostate-specific antigen (PSA) concentrations in hypogonadal men during 6 years of transdermal testosterone treatment. Raynaud JP; Gardette J; Rollet J; Legros JJ BJU Int; 2013 May; 111(6):880-90. PubMed ID: 23294726 [TBL] [Abstract][Full Text] [Related]
10. Testosterone replacement therapy in hypogonadal men at high risk for prostate cancer: results of 1 year of treatment in men with prostatic intraepithelial neoplasia. Rhoden EL; Morgentaler A J Urol; 2003 Dec; 170(6 Pt 1):2348-51. PubMed ID: 14634413 [TBL] [Abstract][Full Text] [Related]
11. Factors influencing prostate-specific antigen response among men treated with testosterone therapy for 6 months. Morgentaler A; Benesh JA; Denes BS; Kan-Dobrosky N; Harb D; Miller MG J Sex Med; 2014 Nov; 11(11):2818-25. PubMed ID: 25131184 [TBL] [Abstract][Full Text] [Related]
12. Optimal diagnostic measures and thresholds for hypogonadism in men with HIV/AIDS: comparison between 2 transdermal testosterone replacement therapy gels. Blick G Postgrad Med; 2013 Mar; 125(2):30-9. PubMed ID: 23816769 [TBL] [Abstract][Full Text] [Related]
13. Testosterone replacement for hypogonadism after treatment of early prostate cancer with brachytherapy. Sarosdy MF Cancer; 2007 Feb; 109(3):536-41. PubMed ID: 17183557 [TBL] [Abstract][Full Text] [Related]
14. Testosterone replacement therapy in patients with prostate cancer after radical prostatectomy. Pastuszak AW; Pearlman AM; Lai WS; Godoy G; Sathyamoorthy K; Liu JS; Miles BJ; Lipshultz LI; Khera M J Urol; 2013 Aug; 190(2):639-44. PubMed ID: 23395803 [TBL] [Abstract][Full Text] [Related]
15. Correlation between simultaneous PSA and serum testosterone concentrations among eugonadal, untreated hypogonadal and hypogonadal men receiving testosterone replacement therapy. Grober ED; Lamb DJ; Khera M; Murthy L; Lipshultz LI Int J Impot Res; 2008; 20(6):561-5. PubMed ID: 18843272 [TBL] [Abstract][Full Text] [Related]
16. Testosterone supplementation does not worsen lower urinary tract symptoms. Pearl JA; Berhanu D; François N; Masson P; Zargaroff S; Cashy J; McVary KT J Urol; 2013 Nov; 190(5):1828-33. PubMed ID: 23764078 [TBL] [Abstract][Full Text] [Related]
17. Effect of testosterone replacement therapy on prostate tissue in men with late-onset hypogonadism: a randomized controlled trial. Marks LS; Mazer NA; Mostaghel E; Hess DL; Dorey FJ; Epstein JI; Veltri RW; Makarov DV; Partin AW; Bostwick DG; Macairan ML; Nelson PS JAMA; 2006 Nov; 296(19):2351-61. PubMed ID: 17105798 [TBL] [Abstract][Full Text] [Related]
18. Pharmacokinetic evaluation and dosing of subcutaneous testosterone pellets. Pastuszak AW; Mittakanti H; Liu JS; Gomez L; Lipshultz LI; Khera M J Androl; 2012; 33(5):927-37. PubMed ID: 22403285 [TBL] [Abstract][Full Text] [Related]
19. Racial differences in hypogonadal improvement and prostate-specific antigen levels in hypogonadal men treated with testosterone replacement therapy. Coward RM; Simhan J; Carson CC Int Braz J Urol; 2010; 36(6):700-7; discussion 707-9. PubMed ID: 21176276 [TBL] [Abstract][Full Text] [Related]
20. Testosterone replacement therapy among elderly males: the Testim Registry in the US (TRiUS). Bhattacharya RK; Khera M; Blick G; Kushner H; Miner MM Clin Interv Aging; 2012; 7():321-30. PubMed ID: 22956867 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]